Month: July 2024

Mr. Xuan Liang: Extraordinary Inventor Driving the Development in the Field of Business and Technology

Mr. Xuan Liang is an extraordinary professional in the fields of business and technology development. His achievements include multiple revolutionary inventions and technology developments.

Due to his extraordinary expertise, Mr. Liang provided the world two revolutionary inventions:

–  Mr. Liang invented an automatic LCD monitor production control system which witnessed a through output of 10 million LCD monitors per year–  Mr. Liang invented the configure-to-order based MES

Due to his work, Mr. Liang was awarded the following patent:

CN1696945 Production information control system and methodology CN1696945 Production information control system and methodology; CN CN1696945 · Issued Nov 6, 2005CN CN1696945 · Issued Nov 6, 2005.

Specifically, this invention enables designs, a practical way, to collect production data from massive production lines in order to use the data for quality control and production monitoring.

As the electronics manufacturing industry is booming, more and more electronics companies are competing or collaborating with world-class electronics companies. They have found that traditional shop floor management methods can’t meet the demands of flexible manufacturing, rapid response, and accurate traceability. As the market shifts from large-scale manufacturing to small-volume but diverse manufacturing models, it is imperative to invent a new Configure-to-Order (CTO) Manufacturing Execution System (MES) that can support the shop floor to accept a large number of orders with very different configurations and be able to produce the orders without quality problems and ship them on time.

Mr. Liang has provided the world an explanation of how the Configure-to-Order MES is designed and implemented in an company’s focusing on computer OEM manufacturing. The main work of his work includes:

1. An in-depth definition of the requirements and scope of the CTO MES.2. The system structure, model and technical implementation methods.3. How to develop the core functions of the MES system, including: system control (System Console), process data collection & control interface (Process Control Interface), work-in-progress management (WIP Management) and related business logic.4. Benefits after the implementation of this CTO MES.

Benefits of Mr. Liang’s Technological/Business Development Contributions:

With the help of Mr. Liang’s invention, the CTO MES was implemented in four business units accounting for $500 million in annual sales.  Further, with the implementation of CTO MES, a manufacturing department can shift production of different products from a maximum of 2 times per shift to a maximum of 20 times per shift. This kind of manufacturing flexibility helped the company create an entirely new production model that protected its competitive advantages and enable them to become a world-renowned, successful OEM player.

With the implementation of configure-to-order based MES, business units can automatically receive thousands of orders from the customer’s systems that receive orders from their websites without human intervention, then automatically push the work orders to the shop floor with the clear instructions of assembly and testing, the shop floor workers are able to prepare the different manufacturing materials in the right order, and shift from one batch of low-volume products to another batch with even less quantity. At the end of production, product package labels can be automatically printed and stored in the correct order. At the same time, all the key data of the manufacturing process is sent back to the ERP, so that it can share the manufacturing information with the company’s customers.

Further Benefits, Specific to the customer of the LCD monitor production control system: 

Several months after the LCD monitor control system went live and stabilized, the company began to enjoy the benefits that the system brings through automation.

Two years after the system implementation, the company has improved its burn-in room utilization rate from 70% to 88%. The average test cycle time of the four test stations was reduced from 4 minutes to 2 minutes. The company reached its peak production throughput of 40,000 LCD monitors per day from 20,000. The business unit has achieved their goal of doubling their revenue from $650M to $1.3B by improving their efficiency through automation and better process control. The company is successfully maintaining their competitive advantages as the world’s most efficient LCD monitor manufacturer.

(Article Author: Kandy Chen, Director of Shenzhen Ysemi Computing Co., Ltd.)

Media Contact
Company Name: Xuan Liang
Contact Person: George Liang
Email: Send Email
Country: United States
Website: https://www.linkedin.com/in/george-liang-mi/

Metastatic Triple Negative Breast Cancer Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations by DelveInsight | BioLite, Pfizer, ModernaTX, Inc, Zenith Epigenetics, BioLite, Abbisko

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Metastatic Triple Negative Breast Cancer pipeline constitutes 6+ key companies continuously working towards developing 6+ Metastatic Triple Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Metastatic Triple Negative Breast Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Triple Negative Breast Cancer Market.

 

The Metastatic Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Metastatic Triple Negative Breast Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Metastatic Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years. 

  • Metastatic Triple Negative Breast Cancer companies working in the treatment market are G1 Therapeutics, AstraZeneca, OncoPep, and others, are developing therapies for the Metastatic Triple Negative Breast Cancer treatment 

  • Emerging Metastatic Triple Negative Breast Cancer therapies in the different phases of clinical trials are- COSELA (trilacicilib), Datopotamab deruxtecan (Dato-DXd), PVX-410, and others are expected to have a significant impact on the Metastatic Triple Negative Breast Cancer market in the coming years.   

  • In February 2024, G1 Therapeutics reported that the independent Data Monitoring Committee (DMC) has recommended the continuation of the Phase 3 trial (PRESERVE 2) of trilaciclib in combination with gemcitabine and carboplatin for initial treatment of metastatic triple-negative breast cancer (mTNBC) until final analysis. The analysis, focusing on Overall Survival (OS) in the intent-to-treat (ITT) population, is anticipated by Q3 2024. The DMC did not identify any safety issues and did not propose any modifications to the study. G1 Therapeutics remains blinded to the data as the interim analysis did not meet early stopping criteria.

  • In May 2023, Shanghai Junshi Biosciences Co., Ltd. announced that the National Medical Products Administration has accepted the supplemental new drug application (sNDA) for toripalimab, an anti-PD-1 monoclonal antibody. This application seeks approval for its use alongside albumin-bound paclitaxel to treat untreated metastatic or recurrent metastatic triple-negative breast cancer with PD-L1 positivity (CPS ≥ 1).

 

Metastatic Triple Negative Breast Cancer Overview

Metastatic Triple Negative Breast Cancer (mTNBC) is an advanced form of breast cancer that lacks three key receptors commonly found in other types of breast cancer: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This absence of receptors makes mTNBC more challenging to treat because it does not respond to hormonal therapies or HER2-targeted treatments.

 

Get a Free Sample PDF Report to know more about Metastatic Triple Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/metastatic-triple-negative-breast-cancer-mtnbc-pipeline-insight

 

Emerging Metastatic Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

  • COSELA (trilacicilib): G1 Therapeutics

  • Datopotamab deruxtecan (Dato-DXd): AstraZeneca

  • PVX-410: OncoPep

  • LY3023414: Eli Lilly and Company

  • Niraparib: Tesaro, Inc.

  • Pembrolizumab: Merck Sharp & Dohme LLC

  • Sacituzumab Govitecan: Gilead Sciences

  • NBE-002: NBE-Therapeutics AG

  • L-NMMA: Novartis Pharmaceuticals

  • Imprime PGG : HiberCell

  • TECENTRIQ: Hoffmann-La Roche

  • IPI-549: Infinity Pharmaceuticals

  • Leronlimab (PRO 140): CytoDyn

  • MDNA11: Medicenna Therapeutics

  • ASTX727: Astex Pharmaceuticals, Inc.

  • AG-01: A&G Pharmaceutical Inc.

  • ZEN003694: Zenith Epigenetics

  • AL101: Ayala Pharmaceuticals, Inc.

  • PMD-026: Phoenix Molecular Designs

  • CDX-1140: Celldex Therapeutics

 

Metastatic Triple Negative Breast Cancer Route of Administration

Metastatic Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Metastatic Triple Negative Breast Cancer Molecule Type

Metastatic Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Metastatic Triple Negative Breast Cancer Pipeline Therapeutics Assessment

  • Metastatic Triple Negative Breast Cancer Assessment by Product Type

  • Metastatic Triple Negative Breast Cancer By Stage and Product Type

  • Metastatic Triple Negative Breast Cancer Assessment by Route of Administration

  • Metastatic Triple Negative Breast Cancer By Stage and Route of Administration

  • Metastatic Triple Negative Breast Cancer Assessment by Molecule Type

  • Metastatic Triple Negative Breast Cancer by Stage and Molecule Type

 

DelveInsight’s Metastatic Triple Negative Breast Cancer Report covers around 6+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Metastatic Triple Negative Breast Cancer product details are provided in the report. Download the Metastatic Triple Negative Breast Cancer pipeline report to learn more about the emerging Metastatic Triple Negative Breast Cancer therapies

 

Some of the key companies in the Metastatic Triple Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for Metastatic Triple Negative Breast Cancer are – Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc.,  Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.

 

Metastatic Triple Negative Breast Cancer Pipeline Analysis:

The Metastatic Triple Negative Breast Cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Triple Negative Breast Cancer Treatment.

  • Metastatic Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Metastatic Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Triple Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Metastatic Triple Negative Breast Cancer drugs and therapies

 

Metastatic Triple Negative Breast Cancer Pipeline Market Strengths

  • Recent approvals of PD-1/PD-L1 and PARP inhibitors in frontline treatment have significantly improved patient prognosis.

  • Entry of the new ADC TRODELVY in the market has also presented itself as an effective treatment option for people progressing from prior lines of therapy.

 

Metastatic Triple Negative Breast Cancer Pipeline Market Opportunities

  • Identification of additional potentially targetable biomarkers and their effective targeting by novel molecules could significantly improve patient outcomes in patients with low expression of known targetable biomarkers like PD-L1 and germline BRCA1/2 mutations.

  • TNBC is a group of diseases, which, with further research and upon improved understanding, is set to be subclassified, which would, in turn, improve treatment allocation and patient prognosis

 

Scope of Metastatic Triple Negative Breast Cancer Pipeline Drug Insight    

  • Coverage: Global

  • Key Metastatic Triple Negative Breast Cancer Companies: G1 Therapeutics, AstraZeneca, OncoPep, and others

  • Key Metastatic Triple Negative Breast Cancer Therapies: COSELA (trilacicilib), Datopotamab deruxtecan (Dato-DXd), PVX-410, and others

  • Metastatic Triple Negative Breast Cancer Therapeutic Assessment: Metastatic Triple Negative Breast Cancer current marketed and Metastatic Triple Negative Breast Cancer emerging therapies

  • Metastatic Triple Negative Breast Cancer Market Dynamics: Metastatic Triple Negative Breast Cancer market drivers and Metastatic Triple Negative Breast Cancer market barriers 

 

Request for Sample PDF Report for Metastatic Triple Negative Breast Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. Metastatic Triple Negative Breast Cancer Report Introduction

2. Metastatic Triple Negative Breast Cancer Executive Summary

3. Metastatic Triple Negative Breast Cancer Overview

4. Metastatic Triple Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Triple Negative Breast Cancer Pipeline Therapeutics

6. Metastatic Triple Negative Breast Cancer Late Stage Products (Phase II/III)

7. Metastatic Triple Negative Breast Cancer Mid Stage Products (Phase II)

8. Metastatic Triple Negative Breast Cancer Early Stage Products (Phase I)

9. Metastatic Triple Negative Breast Cancer Preclinical Stage Products

10. Metastatic Triple Negative Breast Cancer Therapeutics Assessment

11. Metastatic Triple Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Triple Negative Breast Cancer Key Companies

14. Metastatic Triple Negative Breast Cancer Key Products

15. Metastatic Triple Negative Breast Cancer Unmet Needs

16 . Metastatic Triple Negative Breast Cancer Market Drivers and Barriers

17. Metastatic Triple Negative Breast Cancer Future Perspectives and Conclusion

18. Metastatic Triple Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Triple Negative Breast Cancer Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations by DelveInsight | BioLite, Pfizer, ModernaTX, Inc, Zenith Epigenetics, BioLite, Abbisko

WorldLeagueLive! Adds Football Stars Piero & Arat to the Roster

WorldLeagueLive! has officially partnered with international superstars Alessandro Del Piero and football prodigy Arat, integrating them into the game for live face-to-face battles with players and as NFT characters.

The Del Piero and Arat NFTs sold out within 48 hours of their official drop and are now available for secondary purchase through the Element trading market. Players who own these NFTs and link them to their game accounts can use Del Piero and Arat as special players in WorldLeagueLive!

 

 

Alessandro Del Piero, an Italian football superstar, is renowned for his skills as a striker. He became famous as a teenager, seen as the successor to the legend Roberto Baggio. At 14, Del Piero joined Padova’s youth training system and was called up to Juventus by Trapattoni in 1993. Over 19 seasons with Juventus, he scored 290 goals and tallied 143 assists in 705 games, becoming the club’s top scorer. Del Piero also won the World Cup with Italy in 2006 and was inducted into the Italian Football Hall of Fame in 2017. Arat, born in 2013, has already made a name for himself in the football world. Praised by stars like Lionel Messi, he is seen as a future successor to Messi.

The collaboration between WorldLeagueLive! and these football icons merge Web2 and Web3, bringing new energy to football during the European Cup. The rise of NFTs has revolutionized how sports fans interact with their favorite players and teams, offering a new way to engage. Integrating these Del Piero and Arat NFTs in WorldLeagueLive! enhances the game’s playability and allows fans to engage more deeply with their favorite stars. Players can own and trade unique digital assets, representing their support and fandom for certain players and teams.

In-game, Del Piero and Arat will host live broadcasts, bringing players and fans closer together. These sessions provide real-time communication and game commentary, creating an immersive experience you can’t get anywhere else! Through live broadcasts and NFTs, players can directly interact with fans, share their experiences, and strengthen fan loyalty.

WorldLeagueLive! bridges the gap between Web2 and Web3, introducing new gameplay and fostering deep collaboration between stars and Web3 gamers. Fans are not just spectators but active participants and contributors. They can partake in the growth of players and teams while earning income by trading and collecting digital assets.

Looking ahead, WorldLeagueLive! plans to collaborate with more stars and brands, delivering richer content to fans and players.

About WorldLeagueLive!

WorldLeagueLive! (WLL) is a mobile soccer game with a thriving ecosystem. It builds connections between players, fans, and Web3 collectors, while deeply involving sports projects and brands to provide gamers with an immersive experience.

Media Contact
Company Name: World league live
Contact Person: Marketing Team
Email: Send Email
Address:103 TAMPINES STREET 86, #03-06, THE ALPS RESIDENCES
Country: Italy
Website: https://worldleaguelive.com/

Mr. Xuan Liang’s Extraordinary Professional Awards Received Throughout His Career

Mr. Xuan Liang’s extraordinary abilities in the field of business development and technology development have been confirmed by numerous prestigious awards over multiple decades. Mr. Liang’s career awards have included the following:

HKUST Beta Gamma Sigma Award

The HKUST Business School has been a proud Collegiate Chapter of The Beta Gamma Sigma since 2000. Exceptional Business School participants are provided with the opportunity to become inductees representing the HKUST Chapter. Thus, before even being considered for such a huge honor, someone must prove their merits by being accepted into a prestigious MBA program in the first place.  Then, they must stand out above other experts in their field to be inducted.

To be accepted into the MBA program HKUST, applicants must meet several rigorous requirements: A bachelor’s degree from a recognized institution is mandatory; Work Experience: For the full-time MBA program, a minimum of two years of full-time work experience is required. For the part-time program, at least three years of work experience is necessary; GMAT/GRE Scores: Applicants must submit satisfactory GMAT or GRE scores; English Proficiency: If the candidate’s first language is not English, the candidate needs to submit TOEFL, IELTS, or Duolingo English Test scores. The minimum requirements are a TOEFL-iBT score of 80, TOEFL-pBT score of 550, IELTS overall score of 6.5, or a Duolingo score of 125; Interview: Selected applicants must be interviewed as part of admissions process.

To be inducted into Beta Gamma Sigma (BGS) at HKUST’s MBA program, students must meet stringent academic criteria. BGS is an international honor society recognizing academic excellence in business studies, and induction is considered a significant achievement. 

Requirements for Induction: Academic Ranking: Top 20% of Graduate Students: To qualify for induction, MBA students must rank in the top 20% of their class based on their cumulative GPA. For part-time MBA students, the students must rank in the top 5%; Program Accreditation: The business school must be accredited by the Association to Advance Collegiate Schools of Business (AACSB); Nomination and Invitation: Eligible students receive an invitation to join BGS, based on their academic performance.

Difficulty of Achieving Induction: Competitive Academic Environment: HKUST’s MBA program is highly competitive, with many students striving for top grades; High Academic Standards: Maintaining a GPA that places a student in the top 20% requires consistent academic excellence; Selective Process: The selective nature of BGS induction means only the highest-performing students are invited, making it a prestigious recognition.

In the year of 2015, only 193 new members were inducted for this highly prestigious award. Inductees included extraordinary faculty members, PhD graduates, MBA/MSc graduates, and BBA/BSc graduates. Mr. Liang was only one of the three students in his MBA class to receive this highly competitive and prestigious award.

“Foxconn Excellent Supervisor” Awarded Twice (2005 and 2006).

This prestigious recognition is granted solely to supervisory-level professionals. Further, among supervisors, this is awarded to less than 10% of supervisors or an above rank, underscoring its exclusivity.

The criteria for this award are stringent, reflecting high standards of leadership and performance. Supervisors are evaluated on several factors including team productivity, adherence to quality standards, innovative problem-solving, and exemplary leadership qualities. Achieving this award demonstrates a consistent commitment to excellence and a significant positive impact on both team and company performance.

The “Foxconn’s Excellent Supervisor” award is highly competitive, with less than 10% of supervisors receiving the award each year. Only a select number of supervisors at the supervisor level and above are recognized each year.

NeoPhotonics Neo-Semi Project Award

To gain this award, Mr. Liang not only had to find technical solutions for all system related issues, but also had to bridge the cultural gap between the Japanese company and the American company and to implement the technical solutions in a limited time. The latter was extremely difficult to achieve in such a short period, especially for a foreigner without much understanding of Japanese culture.

Among all the project participants, only three people received the awards. Mr. Liang received this award for his extraordinary leadership in the work of finding inventory management solutions and implementing the Factory Information System in the two Neo-Semi factories. 

There were approximately 40 to 50 highly skilled professionals eligible for this award. Of these professionals, only 3 were selected for this highly prestigious award.

(Article Authored by: Aim Khan, Chief Information Officer(Interim), LUMENTUM OPERATIONS LLC)

Media Contact
Contact Person: Xuan Liang
Email: Send Email
Country: United States
Website: https://www.linkedin.com/in/george-liang-mi/

Jessa Carter Hosts Next Financial Fire LIVE: The Ultimate Transformation Experience for Purpose-Driven Entrepreneurs

New York, NY, USA – July 4, 2024 – Jessa Carter, CEO and visionary founder of the Peaceful Billionaire Institute for Wealth Creation, alongside 10 esteemed industry leaders, are uniting to support purpose-driven entrepreneurs to break through financial barriers and achieve maximum Peace, Passion, and Profits at Financial Fire LIVE. This one-day online event will unveil the top cash flow secrets used by each presenter, ensuring participants make 2024 their most prosperous financial year yet.

Financial Fire LIVE is scheduled for July 12, 2024, from 8 AM to 4 PM PST / 11 AM to 7 PM EST, and will be accessible online at www.financialfirelive.com.

With statistics showing that 45% of businesses fail within the first five years, and 20% within the first two, the challenges CEOs and founders face can feel overwhelming.

Jessa Carter understands the struggle all too well. However, Carter emphasizes that beyond strategic planning, the key to overcoming financial hurdles lies in the psychology and skills known by the leaders of an organization. “Personal and professional development are paramount for the growth and success of any business,” says Carter.

Financial Fire LIVE offers tangible tools for entrepreneurs to elevate their profitability and success. Having left a lucrative career in Neurosurgery to pursue her purpose, Carter understands the entrepreneurial journey of uncertainty and risk, and the stress and financial strain that can come with it. Through this event, she aims to provide practical tools and strategies to empower entrepreneurs to achieve their financial goals without compromising their vision or increasing stress levels.

Aligned with her mission to revolutionize wealth creation and empower individuals globally, Financial Fire LIVE represents a pivotal moment in Carter’s vision. By leveraging neuroscience and innovation, she endeavors to make time and financial freedom the standard, eliminating stress, overwhelm, and burnout from the entrepreneurial journey.

Following Financial Fire LIVE, Carter remains committed to supporting purpose-driven entrepreneurs through various avenues, including group coaching, private mentorship, and luxury transformational retreats.

Learn more about Jessa and her recently released book, The Peaceful Millionaire, and receive a signed copy delivered to your door, at www.PeacefulMillionaireNow.com.

To learn more about Financial Fire LIVE and secure your spot at the event, visit www.financialfirelive.com.

About The Peaceful Billionaire Institute for Wealth Creation

The Peaceful Billionaire Institute for Wealth Creation is a trailblazing enterprise dedicated to leveraging Neuroscience and Innovation to revolutionize wealth creation, empower individuals, and transform the financial landscape worldwide. With a steadfast commitment to fostering financial freedom and purpose-driven entrepreneurship, The Peaceful Billionaire Institute is dynamically poised to redefine the future of leadership and individual earning power.

About Jessa Carter

Jessa Carter is known as the Entrepreneur’s Secret Weapon. She is the world’s most highly intuitive Executive Performance Coach and Life and Wealth Mastery Mentor for CEOs, entrepreneurs, and leaders who desire next-level success, wealth, and a life brimming with peace, joy, and fulfillment rather than settling for the typical life of stress and overwhelm.

As the NYC, chair of the Global Leaders Organization, founder of The Peaceful Billionaire Institute for Wealth Creation, and curator of “The Peaceful Billionaire Wealth System,” she excels in re-defining and re-inventing yourself, your life, your business, and your bank accounts to soaring heights that defy logic so that your time on earth is by intentional design, never by default.

Jessa is a maverick of the mind and human-potential pioneer who is on a mission to transform the global financial landscape, make financial freedom the norm, and illuminate 1 million Peaceful Billionaires worldwide. Visit www.PeacefulMillionaireNow.com.

Media Contact
Company Name: Vedette Global Media
Contact Person: Angel Tuccy
Email: Send Email
Phone: 720-257-9263
Country: United States
Website: https://vedettenews.com

Golden Gate Tofu: A Reliable Partner in Soy Products Supply for the Food Service Industry

In the United States, food safety is a critical concern for both the food service industry and consumers. The government continues to strengthen food safety regulations, with the FDA consistently updating related policies and standards to enhance the security and transparency of the food supply chain. Golden Gate Soy Products, as a participant in the soy products industry, understands the importance of food safety and is dedicated to providing safe, healthy soy products.

In 2019, Golden Gate Tofu faced challenges during a production environment inspection but responded swiftly, successfully passing FDA certification and resuming operations. This process not only demonstrated Golden Gate Tofu’s high regard for food safety but also regained the trust of consumers and the food service industry through concrete actions.

Adhering to the strict standards of the Food Safety Modernization Act (FSMA), Golden Gate Tofu ensures that all soy products meet the latest food safety requirements through third-party audits. The company regularly sends product and environmental swabs to laboratories for testing to verify their safety and cleanliness. Additionally, Golden Gate Tofu uses food-grade cleaning chemicals to maintain high standards of cleanliness for production equipment, ensuring the safety and quality of products from the source.

Golden Gate Tofu treats food safety as part of its corporate culture, implementing extensive employee training programs to ensure every employee is familiar with food safety standards and operating procedures. The newly established food safety team is responsible for regularly inspecting and recording every aspect of the production process to ensure all operations meet standards.

To enhance product quality, Golden Gate Tofu has introduced advanced pasteurization equipment. This high-tech equipment can thoroughly eliminate bacteria in tofu without adding preservatives, maintaining the product’s freshness and nutritional value. At the same time, the company has installed fully automated production lines with advanced computer monitoring systems to ensure that every piece of tofu meets the same high standards.

Golden Gate Tofu actively meets the professional needs of the food service industry by offering two featured tofu products: soft tofu and firm tofu, catering to various culinary scenarios. These products, with their unique textures and versatility, adapt to diverse food service applications. Golden Gate Tofu continuously optimizes product development and focuses on product quality, aiming to help food service businesses provide a satisfactory dining experience for their customers.

Golden Gate Tofu’s commitment to food safety extends beyond the present, as the company is dedicated to continuous improvement and innovation. To ensure products meet high standards, every customer receives a Food Safety Guarantee Certificate. Looking ahead, Golden Gate Tofu will continue to focus on continuous improvement in food safety, ensuring consumers can enjoy safe, healthy, and delicious tofu products.

Through the continuous enhancement of technological levels and quality standards, Golden Gate Tofu will continue to provide consumers with safe, healthy, and delicious soy products. Whether for household users or food service businesses, Golden Gate Soy Products is a trustworthy tofu supplier and wholesale partner.

Media Contact
Company Name: Golden Gate Soy Products
Contact Person: Andy Lau
Email: Send Email
Country: United States
Website: https://goldengatetofu.com/

Emerson Law Firm, PC: Expanding with New Office Location

Emerson Law Firm, PC: Expanding with New Office Location

Dallas, Texas – July 4, 2024 – Emerson Tax & Consulting, LLC is excited to announce its grand opening. The business will be located at 16135 Preston Rd, Suite 135, Dallas, TX 75248. We are committed to providing top-tier accounting services in income tax preparation, tax planning, solving of IRS problems, bookkeeping and accounting review, retirement and business cash-flow analysis, estate taxes, and business consulting to individuals, small businesses, consultants, and executives both locally and globally.

Emerson Law Firm, PC

Our Dallas location will allow us to better serve our clients across Texas and further afield in US federal and international tax returns and other matters. Emerson Tax & Consulting, LLC specializes in assisting clients with reducing taxation, solving complex IRS issues, filing comprehensive income tax returns, and solving accounting and cash-flow issues. We also provide a full range of consulting solutions to businesses of all types and in all industries.

What sets Emerson Tax & Consulting, LLC apart is our commitment to transparency and predictability in our costs. We offer most of our services for a reasonable, fixed fee set for the entire calendar year, ensuring our clients financial peace and ease of access to our services without the worry of fluctuating fees.

We invite you to make an appointment for our new office and consult with our team to explore how we can assist you or your business in navigating the complexities of tax issues and business consulting effectively. At Emerson Tax & Consulting, LLC, your financial security and well-being are our top priorities.

About Emerson Tax & Consulting, LLC

Based in Dallas and serving clients throughout Texas and beyond, Emerson Tax & Consulting, LLC is dedicated to helping small businesses, consultants, executives, and individuals efficiently manage their matters in the realms of income taxes, IRS problem resolution, estate taxes, and business consulting. Our mission is to ensure that every client achieves a state of profitability, financial security, and peace of mind.

Media Contact

Jonathan Emerson

Emerson Tax & Consulting, LLC

16135 Preston Rd, Suite 135

Dallas, TX 75248

Phone: 972-282-2461

Website: www.texasbusinesstaxlaw.com

Media Contact
Company Name: Emerson Law Firm, PC
Contact Person: Jonathan Emerson
Email: Send Email
Phone: 972-282-2461
Address:16135 Preston Rd, Suite 135
City: Dallas
State: TX 75248
Country: United States
Website: https://texasbusinesstaxlaw.com/

Gates Drone Services Inc Elevates Real Estate and Hospitality Marketing with Advanced Aerial and Interior Imaging Solutions

Boardman, Ohio – GATES DRONE SERVICES INC, a leading provider of aerial and interior photography services, proudly showcases its comprehensive suite of imaging solutions tailored for the commercial and residential real estate sectors, as well as hotels and resorts. Established in 2019 and led by Karen Gates, the company has become a pivotal force in transforming property presentations through state-of-the-art photographic technologies.

Innovative Imaging Solutions for Real Estate & Hospitality

Based in Boardman, Ohio, GATES DRONE SERVICES INC offers expertise in aerial photography and videography, aerial real estate photography, SceneScape 360, detailed interior photography, 360° views, and comprehensive floor plans. Each service is designed to optimize property presentation and marketing, providing realtors and contractors with the tools they need for enhanced visual engagement and interaction.

Dedicated to Excellence and Detailed Imagery

The company is committed to capturing the essence of each property with a steadfast focus on quality and precision. These offerings enrich online listings and augment the visual content used in promotion and sales strategies. The meticulous attention to detail facilitates a profound visualization that captures the true character and dimensions of a space.

Commitment to Customer Satisfaction and Integrity

GATES DRONE SERVICES INC values the importance of customer relationships, emphasizing integrity, professionalism, and a client-centered approach in all its operations. Through continuous innovation and adapting to client feedback and industry trends, the company ensures that it remains at the cutting edge of aerial and interior imaging.

For additional details about GATES DRONE SERVICES INC and to view their portfolio, please visit Gates Drone Services.

About GATES DRONE SERVICES INC

Founded in 2019 in Boardman, Ohio, GATES DRONE SERVICES INC specializes in high-quality aerial and interior photography, serving commercial and residential real estate markets, as well as the hospitality industry. The company’s innovative solutions significantly elevate client marketing strategies and property presentations.

Media Contact
Company Name: Gates Drone Services
Contact Person: Karen Gates
Email: Send Email
Phone: (727) 492-8605
Country: United States
Website: https://gatesdroneservices.com/

Geoffrey Kent Of Think Big with Geoffrey Kent Honored As Bryn Mawr, PA’s 2024 Local Business Person Of The Year

Geoffrey Kent Of Think Big with Geoffrey Kent Honored As Bryn Mawr, PA’s 2024 Local Business Person Of The Year

The attributes that get you ostracized in corporate America, are the same attributes that will make you wildly successful in entrepreneurship!
Alignable’s 2024 Local Business Person Of The Year Contest reached unparalleled participation levels, logging a whopping 309,000+ votes, 64,000+ recommendations, and an unheard of 5,100 local winners across the U.S. and Canada. The largest online networking platform for business owners, Alignable.com invited its 8.7 million+ members to shout-out local business leaders who’ve gone above and beyond guiding peers and supporting entire communities, amid challenging economic conditions.

Alignable’s 2024 Local Business Person Of The Year Contest reached unparalleled participation levels, logging a whopping 309,000+ votes, 64,000+ recommendations, and an unheard of number of local winners – over 5,100 across the U.S. and Canada. The largest online networking platform for business owners,

Alignable.com invited its 8.7 million+ members to shout-out local business leaders who’ve gone above and beyond guiding peers and supporting entire communities, amid challenging economic conditions.

Today, Alignable’s network announced that Geoffrey Kent of Think Big with Geoffrey Kent has been elected as Bryn Mawr, PA’s 2024 Business Person Of The Year!    

The 2024 contest is the most popular competition Alignable has hosted in over five years, marking a 40% jump in participation over 2023.  During the 2024 contest, which ran from Jan. 8 to Feb. 23, 2024, 5,171 business owners emerged as winners (including ties), across 4,820 communities. That’s an increase of 1,195 additional Local Business People Of 2024 compared to 2023.

These leaders were commended for helping their peers and communities through a year with many challenges, including rising interest rates and rents, not to mention skyrocketing supply costs. “In our local business community, we look out for each other and refer businesses down the street or around the corner to help make everyone in town as successful as possible,” said Kent. “And the challenges we’ve all encountered have compelled many of us to offer counsel to peers fighting to keep their businesses afloat. While I’m thrilled to receive this award, it’s really a testament to our entire community.”  

Kent received a special badge on his Alignable profile, recognizing this big win. In past years, the awareness generated through similar contests has spurred expanded connections, as well as new business for many winners. Driving Recognition, Relationships & Referrals “Our members can’t stop raving about how this contest supercharged the relationships within their networks, which have sparked referrals, ignited fresh business opportunities, and fueled an unstoppable wave of mutual support,” said Eric Groves, CEO and Co-Founder of Alignable. “Small business owners are the vibrant heartbeat of their communities, and it’s high time they got the recognition they deserve. With over 64,000 recommendations pouring in from this year’s contest, it’s crystal clear: when small business owners unite, they become an unstoppable force.”  

To arrange interviews with Geoffrey Kent and/or an Alignable representative, please contact Chuck Casto at chuck@alignable.com. He also can offer JPEGs and other visuals, as well as local winner testimonials.   

About Think Big with Geoffrey Kent:

Think Big with Geoffrey Kenthelps entrepreneurs who are struggling with starting or growing a business venture, by teaching them how to connect entrepreneurship with passion, how to become market dominant using laser focus, how to build highly effective sales advocates using unconventional alliance partners, how to consistently overachieve expectations by measuring and monitoring the right metrics, and how to execute at a world-class level by checking personal ego at the door. 

Reach Geoffrey Kent directly on Alignable Here

Video Link: https://www.youtube.com/embed/X_cr7pI2QU4

Media Contact
Company Name: Think Big with Geoffrey Kent
Contact Person: Geoffrey Kent
Email: Send Email
Phone: 2673982210
Address:P.O. Box 572
City: Bryn Mawr
State: Pennsylvania 19010
Country: United States
Website: https://www.thinkbigwithgeoffreykent.com/

Myopia Pipeline Assessment 2024: Therapies, Clinical Trials, by DelveInsight | Ziemer Group, NIDEK CO., LTD, 2EyesVision, Carl Zeiss AG, Alcon, CooperVision, Topcon Healthcare

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Myopia pipeline constitutes 8+ key companies continuously working towards developing 10+ Myopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Myopia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myopia Market.

 

The Myopia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Myopia Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Myopia treatment therapies with a considerable amount of success over the years. 

  • Myopia companies working in the treatment market are Sydnexis, Inc., Laboratorios Sophia S.A de C.V., Vyluma, Inc., Hai Yen Eye Care, Qilu Pharmaceutical Co., Ltd., Eyenovia Inc., Santen Pharmaceutical, University of Waterloo, iVeena Delivery Systems, Ocumension (Hong Kong) Limited, Cloudbreak Therapeutics, LLC, Bayer, Novartis, Center For Excellence In Eye Care, LENZ Therapeutics, Inc, and others, are developing therapies for the Myopia treatment 

  • Emerging Myopia therapies in the different phases of clinical trials are- SYD-101, Alleance®, NVK-002, BHVI1, QLM3004, Atropine 0.1%, DE-127, ClearCare, IVMED 85, OT-101 Ophthalmic Solution, CBT-009, VEGF Trap-Eye (BAY86-5321), Ranibizumab, ketorolac (Acular LS), Aceclidine + Brimonidine, and others are expected to have a significant impact on the Myopia market in the coming years.   

  • In May 2024, Dopavision, an innovative company focused on revolutionizing pediatric eye care, has revealed topline results from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287). The six-month results of this randomized, controlled trial show that MyopiaX is safe and well-tolerated. MyopiaX employs targeted photobiomodulation to the eye, aiming to control the progression of myopia in children.

  • In October 2023, Vyluma reported positive preliminary outcomes from the second phase of the Phase III Childhood Atropine for Myopia Progression (CHAMP) clinical trial of NVK002. NVK002 is an investigational preservative-free eye drop aimed at managing myopia in children aged three to 17, intended for nightly use.

 

Myopia Overview

Myopia, also known as nearsightedness, is a common vision condition where distant objects appear blurry while close objects can be seen clearly. This occurs when the eye is too long relative to the focusing power of the cornea and lens, causing light rays to focus at a point in front of the retina instead of directly on its surface. Myopia can be corrected with glasses, contact lenses, or refractive surgery.

 

Get a Free Sample PDF Report to know more about Myopia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myopia-pipeline-insight

 

Emerging Myopia Drugs Under Different Phases of Clinical Development Include:

  • SYD-101: Sydnexis, Inc.

  • Alleance®: Laboratorios Sophia S.A de C.V.

  • NVK-002: Vyluma, Inc.

  • BHVI1: Hai Yen Eye Care

  • QLM3004: Qilu Pharmaceutical Co., Ltd.

  • Atropine 0.1%: Eyenovia Inc.

  • DE-127: Santen Pharmaceutical

  • ClearCare: University of Waterloo

  • IVMED 85: iVeena Delivery Systems

  • OT-101 Ophthalmic Solution: Ocumension (Hong Kong) Limited

  • CBT-009: Cloudbreak Therapeutics, LLC

  • VEGF Trap-Eye (BAY86-5321): Bayer

  • Ranibizumab: Novartis

  • ketorolac (Acular LS): Center For Excellence In Eye Care

  • Aceclidine + Brimonidine: LENZ Therapeutics, Inc

 

Myopia Route of Administration

Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Myopia Molecule Type

Myopia Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Myopia Pipeline Therapeutics Assessment

  • Myopia Assessment by Product Type

  • Myopia By Stage and Product Type

  • Myopia Assessment by Route of Administration

  • Myopia By Stage and Route of Administration

  • Myopia Assessment by Molecule Type

  • Myopia by Stage and Molecule Type

 

DelveInsight’s Myopia Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Myopia product details are provided in the report. Download the Myopia pipeline report to learn more about the emerging Myopia therapies

 

Some of the key companies in the Myopia Therapeutics Market include:

Key companies developing therapies for Myopia are – Ziemer Group, NIDEK CO., LTD, 2EyesVision, Carl Zeiss AG, Alcon, Haag-Streit Holding (Metall Zug), CooperVision, Topcon Healthcare Inc., and others.

 

Myopia Pipeline Analysis:

The Myopia pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Myopia with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia Treatment.

  • Myopia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Myopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myopia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Myopia drugs and therapies

 

Myopia Pipeline Market Drivers

  • Increasing Prevalence, Technological Advancements, Growing Awareness, Rising Screen Time, Supportive Government Initiatives, are some of the important factors that are fueling the Myopia Market.

 

Myopia Pipeline Market Barriers

  • However, High Treatment Costs, Limited Access in Rural Areas, Lack of Awareness, Side Effects and Complications, Regulatory Challenges , and other factors are creating obstacles in the Myopia Market growth.

 

Scope of Myopia Pipeline Drug Insight    

  • Coverage: Global

  • Key Myopia Companies: Sydnexis, Inc., Laboratorios Sophia S.A de C.V., Vyluma, Inc., Hai Yen Eye Care, Qilu Pharmaceutical Co., Ltd., Eyenovia Inc., Santen Pharmaceutical, University of Waterloo, iVeena Delivery Systems, Ocumension (Hong Kong) Limited, Cloudbreak Therapeutics, LLC, Bayer, Novartis, Center For Excellence In Eye Care, LENZ Therapeutics, Inc, and others

  • Key Myopia Therapies: SYD-101, Alleance®, NVK-002, BHVI1, QLM3004, Atropine 0.1%, DE-127, ClearCare, IVMED 85, OT-101 Ophthalmic Solution, CBT-009, VEGF Trap-Eye (BAY86-5321), Ranibizumab, ketorolac (Acular LS), Aceclidine + Brimonidine, and others

  • Myopia Therapeutic Assessment: Myopia current marketed and Myopia emerging therapies

  • Myopia Market Dynamics: Myopia market drivers and Myopia market barriers 

 

Request for Sample PDF Report for Myopia Pipeline Assessment and clinical trials

 

Table of Contents

1. Myopia Report Introduction

2. Myopia Executive Summary

3. Myopia Overview

4. Myopia- Analytical Perspective In-depth Commercial Assessment

5. Myopia Pipeline Therapeutics

6. Myopia Late Stage Products (Phase II/III)

7. Myopia Mid Stage Products (Phase II)

8. Myopia Early Stage Products (Phase I)

9. Myopia Preclinical Stage Products

10. Myopia Therapeutics Assessment

11. Myopia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myopia Key Companies

14. Myopia Key Products

15. Myopia Unmet Needs

16 . Myopia Market Drivers and Barriers

17. Myopia Future Perspectives and Conclusion

18. Myopia Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myopia Pipeline Assessment 2024: Therapies, Clinical Trials, by DelveInsight | Ziemer Group, NIDEK CO., LTD, 2EyesVision, Carl Zeiss AG, Alcon, CooperVision, Topcon Healthcare